QUOTE AND NEWS
StreetInsider.com  Sep 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Meridian+Bioscience+%28VIVO%29+Enters+Agreement+with+Premier+Covering+illumigene/9800675.html for the full story.
Benzinga  Jul 14  Comment 
Below are the top diagnostic substances stocks on the NASDAQ in terms of return on investment. The trailing-twelve-month return on investment at Nymox Pharmaceutical (NASDAQ: NYMX) is 73.80%. Nymox Pharmaceutical's revenue for the same period is...
Market Intelligence Center  Jun 2  Comment 
For a hedged play on Meridian Bioscience (VIVO), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Oct. '14 $20.00 covered call for a net debit in the $19.01 area. That is also the break-even stock price for the...
StreetInsider.com  Mar 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Meridian+Bioscience+%28VIVO%29+New+Molecular+Amplification+Test+Cleared+By+FDA/9323699.html for the full story.
Benzinga  Jan 30  Comment 
Below are the small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Neogen (NASDAQ: NEOG) is $225.21 million. Neogen's ROE for the same period is 10.59%. The...
SeekingAlpha  Jan 28  Comment 
By Stephen Simpson, CFA: Small-cap diagnostics company Meridian Bioscience (VIVO) is a curious study in quality and growth and how Wall Street processes those attributes. Meridian has built up a very strong testing business, with high-quality...
StreetInsider.com  Jan 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Dividends/Meridian+Bioscience+%28VIVO%29+Raises+Qtr.+Dividend+5.3%25+to+%240.20%3B+3%25+Yield/9075871.html for the full story.
StreetInsider.com  Jan 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Meridian+Bioscience%2C+Inc.+%28VIVO%29+Reports+In-Line+Q1+EPS/9075869.html for the full story.
StreetInsider.com  Jan 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Guidance/Meridian+Bioscience+%28VIVO%29+Sees+Weak+Q4+Results/9060811.html for the full story.
DailyFinance  Jan 16  Comment 
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced weaker than expected preliminary operating results for the first quarter ended December 31, 2013. Fiscal 2014 First Quarter Preliminary Outlook Due to factors...





You may also be interested in articles related to Meridian Bioscience (VIVO):
 


Meridian Bioscience is a fully integrated life science company, that engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. The immunodiagnostic technologies used in its diagnostic test kits include evarious popular methods used by reference laboratories, hospitals, and physicians' offices. The company also manufactures and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers.[1]

The Company operates in three segments: U.S. Diagnostics, European Diagnostics and Life Science. The company continues to establish a position in tests that can be used near patients, deemed point of care testing (POCT). This close proximity testing allows for immediate diagnosis and treatment of patients, without having to wait hours or even days for results from central laboratories.[1]

Business Growth

During the 2009/2010 flu season (Q3 2009- Q1 2010) Meridian Bioscience saw record high quarterly revenues (and total year 2009 revenues) due largely to an increase in use of its point of care tests, namely those for influenza and respiratory syncytial virus (RSV). Record high influenza infections and the use of RSV tests as a secondary test to influenza drove testing volumes.[1] The company also leveraged the growing use of tests for Clostridium difficile (C.diff) and Helicobacter pylori (H. pylori). The increasing utilazation of these POCT tests has led the company to work on next generation molecular based point of care tests.[1]

Trends and Forces

New outbreaks and infectious diseases continue to arise

Infectious disease are particularlly prone to outbreaks due to strain mutations, lack of immunizations, and development of new diseases.

As an example, for influenza in just the U.S. alone, according to the CDC, every year 5 to 20 percent of the U.S. population gets the flu, causing more than 200,000 hospitalizations and about 36,000 flu related deaths.[2] In 2009, this average was driven higher due to the emergence of the 2009 H1N1 virus (also know as "Swine Flu"). Average estimates for the impact of 2009 H1N1 between April and mid December of 2009 had 55 million people infected, of which 246,000 were hospitalized and over eleven thousand people died due to the virus. Infections were much higher outside of the U.S. and along with it also was testing.[2]

In comparison to seasonal influenza, 2009 H1N1 affected a much different patient population, which also fueled concern and drove testing. According to the CDC, for seasonal flu about 60 percent of hospitalizations and 90 percent of deaths occur in people 65 years and older. While for 2009 H1N1, approximately 90 percent of estimated hospitalizations and 88 percent of estimated deaths occurred in people younger than 65 years old.[2]

Expanded testing needs due to growing aging populations

The diagnostic testing market will continue to be impacted by increases in the aging and treatment populations. According to the U.S. Census Bureau in 2008, over 94 million people, roughly 31 percent of the population, was over the age of 50. This population is growing at just under three percent. Unfortunately, chronic diseases affect older adults disproportionately and, as a result, the U.S. will be increasingly pressured to handle a growing sick population.[3] Even with over 225,000 physician offices in the U.S., the American College of Physicians forecasts an estimated shortage of 44,000-46,000 physicians by 2025.[4] According to the American Hospital Association (AHA), at least half of the emergency departments are at or over capacity, citing a lack of beds as the main reason.[5] The increase in acutely ill patients, coupled with personnel shortages, is straining clinical laboratory resources from providing test results in a timely manner. In order to relieve the growing burden on clinical laboratories, POCT is becoming increasingly adopted to diagnose and treat patients rapidly for improved patient outcomes.

Competition

Meridian Bioscience competes with large manufacturers and distributers of laboratory products, large multinational diagnostics companies, and specialized POCT firms that tend to focus on certain market segments. Its primary competitors are:

  • Thermo Fisher Scientific (TMO)- Thermo Fisher is one of the top sellers of core laboratory consumable products for research labs.
  • Alere Inc (ALR)- is the dominant player in the POCT space and competes with Meridian Bioscience in almost every type of tests that it makes.
  • Beckman Coulter (BEC)- competes with Meridian Bioscience in infectious diseases and pregnancy testing.
  • Quidel (QDEL)- competes with Meridian Bioscience in pregnancy and infectious disease testing.



References

  1. 1.0 1.1 1.2 1.3 Meridian Biosciences 2010 10k
  2. 2.0 2.1 2.2 Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 – April 10, 2010, CDC.gov, May 14, 2010
  3. An Aging Wolrd: 2008 Census.gov
  4. Worsening Primary Care Shortage Predicted American College of Physicians, December 2, 2008
  5. Ehrhardt, Jane Psychiatric Patients Wait in Overcrowded ERs birminghammedicalnews.com, Accessed on May 25, 2011
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki